Objective: While Second Generation Antipsychotics (SGAs) have been shown, in some studies, to be helpful for amelioration of impulsiveness, aggressiveness and moodiness of patients with Borderline Personality Disorder (BPD), there are additional studies that believe that the evidence does not currently support effectiveness of SGAs for overall severity of borderline symptoms. In light of these conflicting reports, we conducted a trial to compare the efficacy and safety of olanzapine vs. aripiprazole with regard to management of BPD. Method: Twenty-four female inpatients, meeting the diagnosis of BPD according to the DSM-IV-TR criteria, were randomly entered into an 8-week parallel group, open-label study for random assignment to olanzapine or aripiprazole (n=12 in each group). The patients were selected from outpatients among clientele of two psychiatric clinics and also inpatients from female wards of Razi psychiatric hospital. Patients were excluded from the trial if any prominent co-morbid mental disorder was present. The primary outcome measure included the Brief Psychiatric Rating Scale (BPRS) for estimation of baseline psychopathology, clinical outcome and treatment response. In addition, the Buss-Durkee Hostility Inventory (BDHI) for the assessment of anger and hostility, and the Clinical Global Impressions-Severity Scale (CGI-S) for assessment of overall illness severity were used as secondary scales. Changes in mean total scores of the BPRS, CGI-S and BDHI were analyzed within each group by means of a paired t test and compared across the two groups by an unpaired t test. Statistical significance was defined as a 2-sided p value < or = to 0.05. In addition, analysis of effect size (ES) by calculation of Cohen's d was performed and recorded. Results: All of the patients remained in and completed the study. According to the findings olanzapine and aripiprazole reduced mean total score of the BPRS about 25.7% and 18.8% in their groups, and thus illustrated a significant improvement of primary outcome measure at the end of the trial, in comparison with baseline (p<0.01 and p<0.04, respectively). In addition, the mean total score of the BDHI improved around 15% with olanzapine and 12.2% with aripiprazole, which was again significant as regards the first drug (p<0.04), but not so concerning the second one (p<0.06). Significant changes in mean total scores of the CGI-S as well were observed in the olanzapine group with a reduction around 20.9% (p<0.03). Once more, improvement of the same scale by aripiprazole, even though remarkable (19.3%), was not statistically significant (p<0.07). The analysis of specific BPRS subscales in both groups revealed similar, significantly lower scores in anxiety, tension, depressive mood and hostility. In this regard, olanzapine showed appreciably better results on uncooperativeness and excitement, and aripiprazole showed superior efficacy as regards suspiciousness and unusual thought content. The effect size (ES) analysis for changes on the BPRS indicated a large improvement with both olanzapine and aripiprazole. Post-hoc analysis showed an intermediary power=0.46 forof this trial. The mean modal doses of olanzapine and aripiprazole during the trial were 6.4 mg/day (s.d.=2.7) and 7.0 mg/day (s.d.=2.5), respectively. Conclusion: In spite of somewhat comparable effects, it seems that olanzapine, in comparison with aripiprazole, is more effective on borderline personality symptoms.
INTRODUCTION
Serotonin Selective reuptake inhibitors (SSRIs), Second Generation Antipsychotics (SGAs) and mood stabilizers have been used mainly for amelioration of impulsiveness, aggressiveness and moodiness of patients with Borderline Personality Disorder (BPD) 1 . In recent years, the rising utilization of atypical antipsychotics has become the favored approach by most clinicians. This is due to the evident reduction in the aforesaid cluster of symptoms, without substantial extra-pyramidal side effects. There have been a number of trials that have shown that olanzapine, risperidone, quetiapine and aripiprazole were efficacious in treatment of impulsivity and affective symptoms in BPD 1 . In a dd i t i o n , i n c o m p a r i s o n w i t h t y p i c a l antipsychotics, according to a further study, there was no difference between olanzapine and haloperidol with respect to management of BPD 2 . Then again, while according to some studies, aripiprazole, as a newer SGA, is a safe and effective agent in the short-term and long-term treatment of patients with BPD 3, 4 , there are other studies concluding that the evidence does not currently support the effectiveness of mood stabilizers and second-generation antipsychotics for overall severity of BPD and that pharmacotherapy should be targeted at specific symptoms 5 . In light of these contradictions, we conducted a trial to compare the efficacy and safety of olanzapine vs. aripiprazole with regard to management of BPD.
METHOD
This study was carried out with BPD patients attending the department of psychiatry of the university of social welfare and rehabilitation sciences in Razi Psychiatric Hospital, south east of Tehran, and two psychiatric clinics of the University of Azad, a district of Tehran.
Study Sample
Twenty four female inpatients, meeting the Disorders, 4 th edition, text revision criteria (DSM-IV-TR) for Borderline Personality Disorder (BPD), were randomly entered into one of the two contemporaneous groups (n=12 in each group), after full explanation of the procedure and obtaining written informed consent from the participants. In addition, procedural approval of the study was obtained from the related ethical committee of the university.
Diagnostic and Statistical Manual of Mental
The patients were selected from outpatients among clientele of two psychiatric clinics and also inpatients from the female wards of Razi Psychiatric Hospital.
Following admission and a mandatory 7-day washout period, both groups began an 8-week parallel group, open-label study for random assignment to olanzapine or aripiprazole in a 1:1 ratio. Patients were excluded from the trial if any prominent co-morbid mental disorder was present, including: Major Depressive Disorder, Bipolar disorder, Psychosis or Substance Dependency in Axis I, Mental Retardation in Axis II or Identifiable Neurological Morbidity in Axis III.
Study Instruments
The primary outcome measure was the Brief Psychiatric Rating Scale (BPRS) for estimation of baseline psychopathology, clinical outcome and treatment response. In addition, the Buss-Durkee Hostility Inventory (BDHI) for the assessment of anger and hostility, and the Clinical Global Impressions-Severity Scale (CGI-S) for assessment of overall illness severity, were used as secondary scales. The duration of this trial was eight weeks. Assessments were conducted at baseline, and at the end of the experiment. No other concurrent psychotropic medication or psychosocial interventions were allowed during the testing. The drugs were started at 2.5 mg daily and then individually increased weekly by 2.5 mg increments, as needed or tolerated, to a maximum of 10 mg by week 4. The dose established by week 4 was held constant throughout the remainder of the study.
Statistical Analysis
Comparison of demographic characteristics between groups, was done by use of the Student t test. Statistical significance was defined as a 2-sided p value < or = to 0.05. Changes in mean total scores of the BPRS, CGI-S and BDHI were analyzed within each group by means of paired t tests and compared across the two groups by unpaired t tests. In addition, analysis of effect size (ES) by calculation of Cohen's d and the effect size correlation was performed and recorded.
RESULTS
There were no significant differences in background characteristics between the two treatment groups and analysis for efficacy was based on data from the same number of patients in both groups (n=12 in each), because all of the patients remained in and completed the entire 8 weeks of the study. Mean age of the patients in the olanzapine and aripiprazole groups were 28.0±9.6 and 26.8±8.7 years old, respectively (t=0.32, p<0.75).
The mean modal doses of olanzapine and aripiprazole during the trial were 6.4 mg/day (s.d.=2.7) and 7.0 mg/day (s.d.=2.5), respectively.
According to the findings olanzapine and aripiprazole reduced the mean total score of the BPRS about 25.7% and 18.8% in their groups, and thus illustrated a significant improvement in the primary outcome measure at the end of the trial, in comparison with baseline (p<0.01 and p<0.04, respectively) (Table 1) .
Although, olanzapine caused decrement greater decrease in the BPRS score, betweengroup analysis showed no significant differences between the groups at week 8, a finding that was comparable as well to other outcome measures in the present assessment (Table 2 ).
In addition, the mean total score of the BDHI improved around 15% with olanzapine and 12.2% with aripiprazole, which was again significant as regards the first drug (p<0.04), but not so concerning the second one (p<0.06) (Table2).
Significant changes in mean total scores of the CGI-S as well were observed in the olanzapine group with a reduction around 20.9% (p<0.03). Once more, improvement of the same scale by aripiprazole, even though remarkable (19.3%), was not statistically significant (p<0.07).
The analysis of specific BPRS subscales in both groups revealed similar, significantly lower scores in anxiety, tension, depressive mood and hostility (Tables 3 and 4) . In this regard, olanzapine showed appreciably better results on uncooperativeness and excitement, and aripiprazole showed superior efficacy as regards suspiciousness and unusual thought content. Other BPRS factors failed to reach statistical significance. Moreover, since the sample size was small, the effect size (ES) was analyzed for changes on the BPRS at the end of treatment, which indicated a large (d= or > 0.8), readily observable improvement with both olanzapine (Cohen's d=1.0, effect-size r=0.4) and aripiprazole (Cohen's d=0.8, effect-size r=0.3). Post hoc analysis showed an intermediary power= 0.46 for of this trial, which became power= 0.76 in compromise power analysis.
W e i g h t g a i n ( n = 3 , m e a n w e i g h t gain=0.6±0.08kg) somnolence (n=4), dizziness (n=2) and tremor (n=1) in the olanzapine group, and tremor (n=1), inner restlessness (n=2), akathisia (n=1), headache (n=1) and insomnia (n=1) in the aripiprazole group were among the major side effects that were noted through the weekly visits and clinical examinations in the inpatient setting of the hospital. Since the side effects were mild and well tolerated, no subject failed to complete the study, due to medication intolerance.
DISCUSSION
The primary objective of this study was to compare the efficacy and safety of olanzapine and aripiprazole in patients with BPD. It is worth mentioning that, because of high comorbidity of BPD with Axis I disorders, participants often report other disorders whose presence may complicate response to any medication. Without this comorbidity, as is the case in the current study, the results may not be generalizable to clinical practice. In addition, people with BPD are prone to high placebo response rates, and impulsivity may resolve spontaneously which means that open-label trial data should be interpreted with caution 6 . According to the results, both agents showed s i g n i f i c a n t i m p r o v e m e n t o f b a s e l i n e psychopathology and primary outcome measure (BPRS) at the end of the trial, while between-group analysis did not show any significant difference between them. But with respect to "anger and hostility" and "overall illness severity", based on the mean total scores of the BDHI and CGI-S, respectively, at the end of the assessment, a significant response was evident only in the olanzapine group in comparison with the aripiprazole group, a finding that was not significant in between-group analysis. Such a difference perhaps would disappear after a longer duration of assessment, with a larger sample or even with a more exact equivalence of the dosages of the drugs, particularly when the analysis of specific BPRS subscales in both groups had revealed comparable and significantly lower scores in anxiety, tension, depressive mood and hostility. In addition, the differences regarding better outcome on uncooperativeness and excitement by olanzapine and suspiciousness and unusual thought content by aripiprazole might fade away by taking into account the above-mentioned variables. In addition, the obvious large improvement with both olanzapine and aripiprazole, based on the analysis of effect size (ES), was evidence in favor of comparable efficacy of both of them.
The findings of this trial are in agreement with previous studies with respect to the usefulness of olanzapine 7, 8 and aripiprazole 3,4 on borderline symptoms, but are not in complete agreement with Lieb et al. regarding the uncertain effect of SGAs on the "overall severity" of BPD 5 . For example, while Nickel et al. observed significant changes in their short-term and longterm studies on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state-trait anger expression inventory (STAXI) in aripiprazoletreated subjects 3,4 , Lieb et al., in a Cochrane Collaboration systematic review and meta-analysis of randomized comparisons of drug vs. placebo, drug vs. drug, or single drug vs. combined drug treatment in adult patients with BPD found that drug treatment, especially with mood stabilizers and second-generation antipsychotics, may be effective for treating a number of core symptoms and associated psychopathology, but the evidence does not currently support effectiveness for overall severity of BPD, and so pharmacotherapy should be targeted at specific symptoms 5 . Nonetheless, the current difference between these two drugs regarding "anger and hostility" and "overall illness severity", based on the mean total scores of the BDHI and CGI-S (respectively), on their better outcomes on some of the specific BPRS subscales (like.g. anxiety, tension, depressive mood and hostility), and on the slight differences with respect to uncooperativeness, excitement, suspiciousness and unusual thought content, shows that the attitude of Lieb et al. regarding 'targeting specific symptoms by pharmacotherapy' is logical 5 . Therefore, further and more detailed studies regarding this issue seem to be necessary.
In this regard, Bruno et al. reported the case of a 37-year-old obese woman with BPD, obsessivecompulsive symptoms and bulimia nervosa, who was treated with aripiprazole and topiramate. According to this study, co-administration of aripiprazole and topiramate could be a safe and effective long-term treatment for improving not only the symptoms of BPD but also health-related quality of life and interpersonal problems 9 . More weight gain, somnolence and dizziness in the olanzapine group and akathesia, headache and insomnia in the aripiprazole group, indicate that clinicians should take into account the different side effect profile of drugs alongside the efficacy. Further risk of metabolic problems by atypical antipsychotics, especially olanzapine, in longterm management, necessitates reasonable safety measures with respect to curative plans and impending adverse effects.
Advantages and limitations of the study
The open-label procedure, small sample size, short duration of assessment, inexactly comparable doses, and gender-based sampling were among the weak points of this trial. Therefore, one should be cautious in generalizing the results of this assessment. The advantages of this study are that all of the cases completed the entire 8 weeks of the study and therefore all of them were retained throughout the evaluation, and that both groups had comparable baseline features and equal numbers of patients.
CONCLUSION
In spite of somewhat comparable effects, it seems that olanzapine, in comparison with aripiprazole, was more effective on borderline personality symptoms.
